Travere Therapeutics, Inc. reported $591M of revenue over the trailing twelve months, +77% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $591M (to Q2 2026). Net income: −$43M, trailing twelve months to Q2 2026. Operating margin: −9.1%, trailing twelve months to Q2 2026. EPS: −$0.46, trailing twelve months to Q2 2026.

TVTXTravere Therapeutics, Inc.

Healthcare

$52.12+110% 1Y

$52.12

$23.9052 weeks$67.51

TVTX as reported

Travere Therapeutics, Inc. reported $591M of revenue over the trailing twelve months, +77% on the year before. 10 reported series are charted on this page, each one as filed.

$591M

Revenue, trailing twelve months · to Q2 2026 · +77% against the twelve months before

Net income: −$43M
Net income · −74% year on year · trailing twelve months to Q2 2026
Operating margin: −9.1%
Operating margin · trailing twelve months to Q2 2026
EPS: −$0.46
EPS · −77% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for TVTX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$591M	+77%	Q2 2026
Net income	−$43M	−74%	Q2 2026
EPS	−$0.46	−77%	Q2 2026
Gross margin	99%	n/a	Q2 2026
Operating margin	−9.1%	n/a	Q2 2026
Net margin	−8.0%	n/a	Q2 2026
ROE	−85%	n/a	Q2 2026
ROA	−7.5%	n/a	Q2 2026
ROIC	−42%	n/a	Q4 2015 · 42 quarters behind
Free cash flow	−$318M	n/a	Q4 2024 · 6 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.